Where is Oxervate (cenegermin) manufactured, and what drives those location costs?
Oxervate (cenegermin) is manufactured in facilities that meet stringent regulatory requirements for biological products. For biologics like cenegermin, manufacturing location costs are driven less by “country labor rates” alone and more by the cost of meeting controlled production conditions and quality systems. Key cost factors typically include the price of qualified facility capacity, compliance, and the logistics of maintaining cold-chain materials from site to site.
What cost factors raise manufacturing expense for a biologic like cenegermin?
Manufacturing a protein-based drug generally becomes expensive at the stage of building and operating:
- cGMP biomanufacturing capacity (clean rooms, controlled environmental systems, validated equipment)
- in-process testing and release testing (lab capacity, reagents/consumables, and skilled technical labor)
- quality assurance and documentation (batch record systems, deviations/OOS investigation processes)
- sterility, containment, and biosafety controls (often requiring dedicated infrastructure)
- validated cold-chain storage and packaging (especially for intermediate materials and finished drug)
These drivers are usually reflected in the operating cost structure more than in raw ingredient costs.
How do cold-chain and distribution requirements affect overall manufacturing/location costs?
If cenegermin drug substance or finished product requires strict temperature control, manufacturing sites must be set up to handle:
- temperature-controlled holding during processing and before fill-finish
- validated transfer to packaging and distribution partners
- cold-chain packaging validation and added logistics handling
- contingency planning to reduce excursion risk
In practice, the location that can reliably support these requirements often has higher overhead, which pushes up unit costs.
Do patents or market exclusivity affect pricing more than manufacturing location?
Even when manufacturing location drives costs, the final price in many markets is also shaped by exclusivity periods, reimbursement negotiations, and competition. Patent and exclusivity timing can determine how much pricing power a manufacturer has while competitors are blocked. For context on exclusivity/patent landscape for Oxervate, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/ [1]
Can different sites change cost structure over time?
Yes. If production capacity is expanded or shifted (for example, to a second fill-finish location), costs can change due to:
- learning curve and yield improvements after ramp-up
- differences in local compliance and utilities costs
- changes in supply chain terms for raw materials and packaging components
- batch scheduling and capacity utilization (which can materially affect cost per unit)
What information would confirm Oxervate’s exact manufacturing locations?
To pinpoint “manufacturing location” specifically (city/site and which steps occur there), you typically need one or more of the following for cenegermin:
- the EU/US product label and packaging insert (manufacturer addresses)
- regulatory filings that list sites and manufacturing stages
- inspections or inspection summaries where available
If you share the country/market you care about (US vs EU vs UK) or the label you’re looking at, I can help interpret where the label points for manufacturing and how that ties to cost drivers.
Sources:
1. https://www.drugpatentwatch.com/